Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
:PBYI
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.1Same Quarter Last Year
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 21.07%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive advancements in clinical trials and regulatory approvals, as well as ongoing challenges with revenue and prescription declines. While the company continues to maintain a positive net income, the drop in royalty revenue and NERLYNX net product revenue raises concerns.Company Guidance
During the fourth quarter of 2024, Puma Biotechnology reported total revenue of $59.1 million, with product revenue net from NERLYNX sales at $54.4 million, a slight decline from $56.1 million in Q3 2024 but an increase from $53.2 million in Q4 2023. The product revenue was influenced by a $3.7 million inventory increase at specialty pharmacies and distributors. Royalty revenue was $4.7 million, a decrease from $24.4 million in Q3 2024 and $19.0 million in Q4 2023, due to lower sales to China. NERLYNX's ex-factory bottle sales reached 2,964 in Q4 2024, up 9% from Q3 2024. New prescriptions (NRx) declined by 7% from the previous quarter, while total prescriptions (TRx) increased by 4%. For fiscal year 2025, Puma anticipates NERLYNX product revenue net in the range of $192 million to $198 million, with a gross to net adjustment between 20.5% and 21.5%. The company also expects royalties between $20 million and $24 million and projects net income for the year between $23 million and $28 million.Increased NERLYNX Bottle Sales
NERLYNX ex-factory bottle sales in Q4 2024 were 2,964, representing an approximate 9% increase quarter-over-quarter and a 3% increase year-over-year.
New Regulatory Approvals
NERLYNX received regulatory approval in Turkey for the extended adjuvant setting and in Thailand for both extended adjuvant and metastatic breast cancer.
Positive Net Income
Net income for the fourth quarter of 2024 was $19.3 million, or $0.39 per share, with an expectation of positive net income for the full year 2025 in the range of $23 million to $28 million.
Revenue Growth in Specialty Distributor Channel
The addition of BioCare to the SD distribution network supports a significant portion of business driven by community oncologists.
Ongoing Clinical Trials Progress
Phase 1 trial for neratinib and trastuzumab deruxtecan, and two Phase 2 trials for alisertib in breast and lung cancer are progressing, with interim data expected in 2025.
---
PBYI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PBYI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $2.99 | $3.58 | +19.73% |
| Nov 07, 2024 | $3.03 | $2.88 | -4.95% |
| Aug 01, 2024 | $3.50 | $3.83 | +9.43% |
| May 02, 2024 | $4.96 | $4.86 | -2.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Puma Biotechnology (PBYI) report earnings?
Puma Biotechnology (PBYI) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Puma Biotechnology (PBYI) earnings time?
Puma Biotechnology (PBYI) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PBYI EPS forecast?
PBYI EPS forecast for the fiscal quarter 2025 (Q1) is -0.02.
---